Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals LP

IPR2025-00056

Dr. Falk Pharma GmbH successfully challenged a pharmaceutical patent (11260061) in an IPR, showing a reasonable likelihood of prevailing on grounds of obviousness (§ 103). The Board's decision hinged on extensive claim construction, particularly defining 'adsorbed onto a pharmaceutically acceptable carrier.'

Jurisdiction
US PTAB
Case Number
IPR2025-00056
Judge(s)
JOHN G. NEW, ZHENYU YANG, RYAN H. FLAX
Decision Date
24 October 2024

Detailed Summary

Dr. Falk Pharma GmbH (Petitioner) challenged the validity of U.S. Patent 11260061 before the PTAB, asserting obviousness over prior art references including Perrett and Dohil2009 under 35 U.S.C. § 103. The Board found that Petitioner showed a reasonable likelihood of prevailing on Ground 1 (Perrett). A key component of the decision involved claim construction, where the Board defined 'adsorbed onto a pharmaceutically acceptable carrier' as meaning 'adhered to or retained on a surface of a pharmaceutically acceptable carrier.' This finding allowed the Petitioner to advance arguments that the blending process in Perrett implicitly leads to the claimed adsorption limitation.

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Dr. Falk Pharma GmbH vs Ellodi Pharmaceuticals LP is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call